Endometrial thickness as a biomarker for ongoing pregnancy in IUI for unexplained subfertility: a secondary analysis
Authors:
- N A DanhofNDN A Danhof
- R van EekelenRER van Eekelen
- S ReppingSRS Repping
- F van der VeenFVF van der Veen
- M van WelyMWM van Wely
- M H MochtarMMM H Mochtar
- SUPER Study groupSGSUPER Study group
- Carolien KoksCKCarolien Koks
- J GianottenJGJ Gianotten
- Jan Peter de BruinJBJan Peter de Bruin
- B J CohlenBCB J Cohlen
Open Access
- 1 January 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2020 (1) , hoz024
Abstract
What is, in couples with unexplained subfertility undergoing IUI, the impact of gonadotrophins compared to clomiphene citrate (CC) on endometrial thickness (EMT) in relation to ongoing pregnancy? In women with unexplained subfertility undergoing IUI with ovarian stimulation, gonadotrophins lead to a thicker endometrium compared to CC, but this does not affect ongoing pregnancy rates. A systematic review and meta-analysis among couples with unexplained subfertility undergoing IUI with ovarian stimulation showed that women who conceived had, on average, a thicker endometrium than women who did not conceive, but this evidence is not robust due to a high level of heterogeneity. There was insufficient data to draw any conclusions on EMT and the effect on pregnancy outcomes. We performed a secondary analysis of a multicentre randomized controlled superiority trial in couples with unexplained subfertility undergoing IUI with adherence to strict cancellation criteria. In total, 738 couples recruited between July 2013 and March 2016 were allocated to ovarian stimulation with gonadotrophins (n = 369) or with CC (n = 369) for a maximum of four IUI cycles. According to local protocol, recombinant FSH, urinary FSH or hMG was used. Natural conceptions and cancelled cycles were removed from this secondary analysis, as they do not provide any information on pregnancy in relation to stimulation after IUI. Ongoing pregnancy was defined as a positive heartbeat at or beyond 12 weeks of gestation. We first determined the difference in EMT between women randomized to gonadotrophins (75 IU) and CC (100 mg) over all cycles using a linear mixed model. We then investigated the association between EMT and ongoing pregnancy after IUI using a logistic regression model, adjusted for the allocated drug, number of dominant follicles, female age, BMI, duration of subfertility, primary or secondary subfertility, referral status, smoking status, cycle number and total motile sperm count. To conclude, we investigated the association between EMT and ongoing pregnancy by logistic regression separately in women allocated to gonadotrophins and in women allocated to CC. A total of 666 couples underwent 1968 IUI cycles. Of these, 330 couples were allocated to gonadotrophins, of which 85 conceived leading to ongoing pregnancy (rate per cycle 8.9%) and 336 couples were allocated to CC, of which 71 conceived leading to ongoing pregnancy (rate per cycle 7.0%) (relative risk (RR) 1.22, 95% CI 0.92 to 1.61). The mean EMT was 8.9 mm (SD 2.1) in women treated with gonadotrophins and 7.5 mm (SD 2.1) in women treated with CC (adjusted mean difference 1.4 mm; 95% CI: 1.1–1.7). The overall mean EMT was 8.4 mm (SD 2.2) in women that conceived leading to ongoing pregnancy and 8.2 mm (SD 2.2) in women that did not conceive (adjusted odds ratio (OR): 1.03 per 1 mm increase, 95% CI 0.95–1.12). There was no association between EMT and ongoing pregnancy in women treated with gonadotrophins or CC (OR: 1.01 per 1 mm increase, 95% CI 0.90–1.13, and 1.10 per 1 mm increase, 95% CI 0.99–1.23, respectively). Since this is a secondary analysis, the data should be interpreted prudently as secondary analyses are prone to false-positive findings or could be underpowered to show associations that the study is not primarily set up for. In women with unexplained subfertility and treated with IUI, gonadotrophins lead to a significantly thicker endometrium compared to CC, but there was no evidence of a consistent association between EMT in women treated with gonadotrophins or CC and the ongoing pregnancy rate. A relatively thin endometrium after CC is therefore not a valid reason to prefer gonadotrophins as the stimulation agent in IUI for unexplained subfertility. The initial trial was funded by the Netherlands Organization for Health Research and Development (ZonMw) (Health Care Efficiency Research; project number: 80-83600-98-10 192). The EudraCT number for this trial was 2013-001034-18. Prof. Dr B.W.J.M. is supported by a NHMRC Practitioner Fellowship (GNT1082548). B.W.M. reports consultancy for Merck, ObsEva and Guerbet. The other authors declare no conflicts of interest. NTR 4057Keywords
Funding Information
- Dutch Organisation for Health Research and Development (ZonMw) Health Care Efficiency Research (80-83600-98-10192)
This publication has 15 references indexed in Scilit:
- Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysisHuman Reproduction Update, 2014
- Effectiveness and treatment for unexplained infertilityFertility and Sterility, 2006
- Effect of clomiphene citrate on endometrium thickness and echogenic patternsInternational Journal of Gynecology & Obstetrics, 2003
- Low Dose of Ethinyl Estradiol Can Reverse the Antiestrogenic Effects of Clomiphene Citrate on EndometriumGynecologic and Obstetric Investigation, 2001
- The Follicle-Stimulating Hormone (FSH) Threshold/Window Concept Examined by Different Interventions with Exogenous FSH during the Follicular Phase of the Normal Menstrual Cycle: Duration, Rather Than Magnitude, of FSH Increase Affects Follicle Development1The Journal of Clinical Endocrinology & Metabolism, 1998
- Endometrial thickness, morphology, vascular penetration and velocimetry in predicting implantation in an in vitro fertilization programUltrasound in Obstetrics & Gynecology, 1995
- Endometrial thickness as measured by transvaginal sonography: interobserver variationUltrasound in Obstetrics & Gynecology, 1994
- Clomiphene citrate affects cervical mucus and endometrial morphology independently of the changes in plasma hormonal levels induced by multiple follicular recruitmentFertility and Sterility, 1993
- Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndromeFertility and Sterility, 1993
- Histology of midluteal corpus luteum and endometrium from clomiphene citrate-induced cyclesFertility and Sterility, 1992